You are here » Home » Companies » Company Overview » Core Healthcare Ltd

Core Healthcare Ltd.

BSE: 500091	Sector: Health care
NSE: COREPARENT	ISIN Code: INE494A01017

BSE 05:30 | 01 Jan

Core Healthcare Ltd

NSE 05:30 | 01 Jan

Core Healthcare Ltd

Core Healthcare Ltd. (COREPARENT) - News Sector

NCLT approves the demerger of Piramal Enterprises' pharma business

12.44 am | 13 Aug 2022 | Business Standard

This paves the way towards creation of two separate listed entities - Piramal Enterprises and Piramal Pharma
F&O Strategy: Nandish Shah recommends a Bull Spread on Lupin

8.27 am | 12 Aug 2022 | Business Standard

The technical analyst from HDFC Securities recommends buying Lupin 700 Call and simultaneously selling 720 Call for the August series.
Max Healthcare Q1 net profit up 12% at Rs 229 cr; revenue rises 5%

3.49 pm | 10 Aug 2022 | Press Trust of India

'Q1FY23 performance reflects normalisation of revenues and operating EBITDA post Omicron wave in the previous quarter,' Max Healthcare Chairman and MD...
Apollo Hospitals acquires asset from Nayati Healthcare for Rs 450 crore

1.56 am | 9 Aug 2022 | Business Standard

The hospital asset was sold by DLF Qutub Enclave Complex Medical Charitable Trust in 2011 to Nayati Healthcare and Research NCR Pvt Ltd
Lupin reports Q1 net loss at Rs 89 cr on lower US sales; revenue falls 12%

9.30 pm | 4 Aug 2022 | Press Trust of India

'Our numbers are muted this quarter, but we expect a strong bounce back from Q2 onwards,' says Lupin MD
Here's why Vinay Rajani recommends buying Indoco Remedies, PTC India

7.54 am | 3 Aug 2022 | Business Standard

The technical analyst from HDFC Securities said traders should wait for correction to enter fresh longs on the Nifty index.
We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD

12.46 pm | 2 Aug 2022 | Business Standard

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda
Piramal Group charts growth path for financial services business

3.46 pm | 1 Aug 2022 | Press Trust of India

'We are on track to achieve retail loan disbursements of Rs 2,500 cr-3,500 cr in Q3FY23,' which is 5-7 times of pre-merger levels, says Piramal Group ...
Sun Pharma stock likely to keep shining amid global specialty scale-up

11.48 pm | 31 Jul 2022 | Business Standard

Focus on key markets to help expand branded formulations business, say experts
Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales

10.06 pm | 29 Jul 2022 | Business Standard

Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million
Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

10.00 pm | 29 Jul 2022 | Business Standard

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%
Top headlines: HDFC Q1 net rises 22%; IOC posts Rs 1,993-cr net loss in Q1

5.27 pm | 29 Jul 2022 | Business Standard

Swiggy announced on Friday that it has extended its 'Future of Work' policy and announced a permanent work-from-anywhere for majority of roles.
Cipla Q1 net profit dips marginally to Rs 706 cr; revenue falls 2%

4.30 pm | 29 Jul 2022 | Press Trust of India

The Mumbai-based company had reported a net profit of Rs 710 crore in the April-June quarter of the last fisca
Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore

11.37 pm | 28 Jul 2022 | Business Standard

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday
Dr Reddy's Q1 PAT soars 108% to Rs 1,188 cr; revenue rises 6%

6.34 pm | 28 Jul 2022 | Press Trust of India

Other operating income was at Rs 600 crore compared to Rs 50 crore in Q1FY22
Top headlines: Dr Reddy's Q1 PAT up 108%; Adani Capital IPO likely in 2024

6.00 pm | 28 Jul 2022 | Business Standard

Bajaj Finserv on Thursday reported a 57 per cent jump in net profit at Rs 1,309 crore in the first quarter ended June 30, on healthy earnings by its s...
Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

12.51 pm | 28 Jul 2022 | Business Standard

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,4...
Here's why Vinay Rajani recommends buying Ajanta Pharma, TTK Prestige

7.46 am | 27 Jul 2022 | Business Standard

The technical analyst also recommends to hold Nifty longs with a stop at 16,300; on the upside, he expects resistance for the NSE benchmark around 16,...
Fitch downgrades Jubilant Pharma to "BB-" indicating higher default risk

2.00 pm | 22 Jul 2022 | Business Standard

Rating agency foresees firm's financial leverage worsening as a rise in capex will coincide with lower profitability
Gland Pharma faces a revenue growth hurdle in FY23; stock falls

11.34 pm | 21 Jul 2022 | Business Standard

The low margin syringes business was impacted by supply chain challenges and shutdown of two manufacturing lines in the domestic market